


Grassypeptolides A–C, Cytotoxic Bis-thiazoline Containing Marine Cyclodepsipeptides

Jason C. Kwan,[†] Ranjala Ratnayake,[†] Khalil A. Abboud,[‡] Valerie J. Paul,[§] and Hendrik Luesch^{*†}

[†]Department of Medicinal Chemistry, University of Florida, 1600 SW Archer Road, Gainesville, Florida 32610, United States, [‡]Department of Chemistry, 214 Leigh Hall, University of Florida, Gainesville, Florida 32611, United States, and [§]Smithsonian Marine Station, 701 Seaway Drive, Fort Pierce, Florida 34949, United States

luesch@cop.ufl.edu

Received July 16, 2010



Grassypeptolides A–C (**1**–**3**), a group of closely related bis-thiazoline containing cyclic depsipeptides, have been isolated from extracts of the marine cyanobacterium *Lyngbya confervoides*. Although structural differences between the analogues are minimal, comparison of the *in vitro* cytotoxicity of the series revealed a structure–activity relationship. When the ethyl substituent of **1** is changed to a methyl substituent in **2**, activity is only slightly reduced (3–4-fold), whereas inversion of the Phe unit flanking the bis-thiazoline moiety results in 16–23-fold greater potency. We show that both **1** and **3** cause G1 phase cell cycle arrest at lower concentrations, followed at higher concentrations by G2/M phase arrest, and that these compounds bind Cu^{2+} and Zn^{2+} . The three-dimensional structure of **2** was determined by MS, NMR, and X-ray crystallography, and the structure of **3** was established by MS, NMR, and chemical degradation. The structure of **3** was explored by *in silico* molecular modeling, revealing subtle differences in overall conformation between **1** and **3**. Attempts to interconvert **1** and **3** with base were unsuccessful, but enzymatic conversion may be possible and could be a novel form of activation for chemical defense.

Introduction

Natural products have historically been a rich source of bioactive compounds and represent a significant portion of marketed drugs, either unchanged or as templates for synthetic modification.^{1,2} In recent years natural products from marine sources have received increased attention,³ in part due to the vast biodiversity of the marine environment, a situation that plausibly increases the need for chemical defenses as a result of

intense competition and predation. As part of our own search for novel bioactive compounds, we have focused on marine cyanobacteria because of their propensity to produce a variety of structures that are frequently toxic to mammalian cancer cells.⁴ Oftentimes, groups of related compounds are produced, sometimes constituting quite large structural families. Such chemical diversity is thought to be an inherent feature of biosynthetic pathways that adapt to changing environments through natural selection⁵ and, through differences in activity, exhibit natural structure–activity relationships. An example

(1) Cragg, G. M.; Grothaus, P. G.; Newman, D. J. *Chem. Rev.* **2009**, *109*, 3012–3043.

(2) Newman, D. J.; Cragg, G. M. *J. Nat. Prod.* **2007**, *70*, 461–477.

(3) Molinski, T. F.; Dalisay, D. S.; Lievens, S. L.; Saludes, J. P. *Nat. Rev. Drug Discovery* **2009**, *8*, 69–85.

(4) Tan, L. T. *Phytochemistry* **2007**, *68*, 954–979.

(5) Jenke-Kodama, H.; Müller, R.; Dittmann, E. *Prog. Drug Res.* **2008**, *65*, 119–140.




FIGURE 1. Structures of grassypeptolide A (1), B (2), and C (3) (a) and of lissoclinamide 7 (b).

of this is the lyngbyastatins/micropeptins,^{6–10} a large group of cyclic depsipeptide enzyme inhibitors that show differing selectivity for elastase, chymotrypsin, and trypsin.

We recently reported the total structure determination of grassypeptolide¹¹ (**1**, Figure 1a),¹² a cyclic depsipeptide that contains several interesting features, including a rare β -amino acid (2-methyl-3-aminobutyric acid, Maba), a large number of D-amino acids, and extensive N-methylation. This compound shares some structural features with the cyanobactins, including lissoclinamide 7 (see Figure 1b). Interestingly, although the cyanobactins are now known to be biosynthesized through a novel ribosomal pathway,^{13–15} **1** is most likely the result of a nonribosomal peptide synthetase (NRPS) system, because of the incorporation of nonproteinogenic units and N-methylation. Although both classes of natural products commonly contain D-amino acids, epimerization is believed to be nonenzymatic in the majority of ribosomal cyanobactins.¹⁶ Like lissoclinamide 7, **1** is cytotoxic to a number of human cancer cell lines. We now report two new analogues of **1**, grassypeptolide B (**2**) and

grassypeptolide C (**3**). While **2** shows cytotoxicity similar to that of **1**, compound **3** is 16–23-fold more potent. Additionally, we demonstrate that **1** and **3** can bind to Cu^{2+} and Zn^{2+} , which may contribute to their activity.

Results and Discussion

Isolation and Structure Determination. Samples of *Lyngbya confervoides* were collected off the Florida Keys as previously described^{12,17} and in a more recent recollection. Compounds **2** and **3** were obtained as minor components of nonpolar extracts (MeOH–EtOAc, 1:1), following silica chromatography and reversed-phase HPLC.

HRESI/APCIMS and NMR data for **2** suggested a molecular formula of $\text{C}_{55}\text{H}_{77}\text{N}_9\text{O}_{10}\text{S}_2$. Compared to **1**, this is a difference of one methylene. The ¹H NMR spectrum of **2** in CDCl_3 is strikingly similar to **1**, except for the presence of a relatively downfield methyl doublet (δ_{H} 1.65, see Table 1 and Table S1, Supporting Information), indicative of an alanine. Indeed, examination of the COSY, edited HSQC and HMBC spectra for **2** revealed the presence of the same units found in **1**, except that Ala was present in the place of 2-aminobutyric acid (Aba). Overall, both proton and carbon chemical shifts of **1** and **2** were comparable, suggesting that the sequence of units and also the relative configuration of both compounds are the same (see Table 1). The sequence could be confirmed easily by examination of HMBC and ROESY correlations (Table S1, Supporting Information).

The obtained yield of **2** was much less than for **1** (1.7 versus 16.4 mg, respectively, from both collections combined). However, by using H_2O to produce a saturated solution, a small amount of crystals could be produced that were adequate for X-ray diffraction studies (see Experimental Section). The resulting structure (Figure 2a) is essentially superimposable to that of **1**, despite the fact that the crystals were formed under different conditions (Figure 2b). As expected, the relative configuration of all stereocenters was the same as that for **1**. Because the Flack x parameter is near zero [0.16 (10)] and the specific rotations shown by **1** and **2** were close in value (+76 versus +109, respectively), the absolute configuration shown is correct.

An additional analogue, compound **3**, was obtained. The HRESI/APCIMS spectrum of **3** suggested a molecular formula of $\text{C}_{56}\text{H}_{79}\text{N}_9\text{O}_{10}\text{S}_2$, the same as that for **1**. Examination of the ¹H NMR, COSY, edited HSQC, HMBC, and ROESY spectra for **3** revealed the presence of the same units present in **1**, namely, 2-methyl-3-aminobutyric acid (Maba), Thr, N-Me-Leu, N-Me-Phe-derived thiazoline carboxylic acid (N-Me-Phe-thn-ca), Pro, N-Me-Val, and phenyllactic acid (Pla). The presence of a 2-aminobutyric acid derived thiazoline carboxylic acid unit was proposed by default, as there were no HMBC or ROESY correlations between the thiazoline ring and the aminobutyric acid portion. Importantly, although the proton and carbon chemical shifts were very similar to those of **1** and **2**, those at position 28 were distinct ($\delta_{\text{H}}/\delta_{\text{C}}$ was 3.83/69.0 and 5.48/59.2 for **1** and **3**, respectively). Second, the methyl signal at position 36 also showed substantially different chemical shifts ($\delta_{\text{H}}/\delta_{\text{C}}$ was 2.78/39.6 for **1** and 3.169/30.7 for **3**). This suggested that **3** was the epimer of **1** at C-28. Examination of correlations in the HMBC and ROESY spectra easily allowed the construction of the

(6) Matthew, S.; Ross, C.; Rocca, J. R.; Paul, V. J.; Luesch, H. *J. Nat. Prod.* **2007**, *70*, 124–127.

(7) Taori, K.; Matthew, S.; Rocca, J. R.; Paul, V. J.; Luesch, H. *J. Nat. Prod.* **2007**, *70*, 1593–1600.

(8) Kwan, J. C.; Taori, K.; Paul, V. J.; Luesch, H. *Mar. Drugs* **2009**, *7*, 528–538.

(9) Ploutno, A.; Shoshan, M.; Carmeli, S. *J. Nat. Prod.* **2002**, *65*, 973–978.

(10) Reshef, V.; Carmeli, S. *Tetrahedron* **2001**, *57*, 2885–2894.

(11) For clarity, hereafter grassypeptolide (**1**) will be referred to as grassypeptolide A.

(12) Kwan, J. C.; Rocca, J. R.; Abboud, K. A.; Paul, V. J.; Luesch, H. *Org. Lett.* **2008**, *10*, 789–792.

(13) Schmidt, E. W.; Nelson, J. T.; Rasko, D. A.; Sudek, S.; Eisen, J. A.; Haygood, M. G.; Ravel, J. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 7315–7320.

(14) Long, P. F.; Dunlap, W. C.; Battershill, C. N.; Jaspars, M. *Chem-BioChem* **2005**, *6*, 1760–1765.

(15) Donia, M. S.; Ravel, J.; Schmidt, E. W. *Nat. Chem. Biol.* **2008**, *4*, 341–343.

(16) McIntosh, J. A.; Donia, M. S.; Schmidt, E. W. *Nat. Prod. Rep.* **2009**, *26*, 537–559.

(17) Kwan, J. C.; Eksioğlu, E. A.; Liu, C.; Paul, V. J.; Luesch, H. *J. Med. Chem.* **2009**, *52*, 5732–5747.

TABLE 1. NMR Spectral Data in CDCl₃ for Grassyseptolide A (1) at 500 MHz (¹H)/100 MHz (¹³C) and B (2) at 600 MHz

| | C/H no. | grassyseptolide A (1) | | grassyseptolide B (2) | |
|-----------------------|---------|----------------------------|----------------------|-----------------------------|--------------|
| | | δ_H (J in Hz) | δ_C^a | δ_H (J in Hz) | δ_C^b |
| Maba | 1 | | 172.5, s | | 172.7, s |
| | 2 | 2.51, qd (6.9, 6.2) | 45.5, d | 2.55, qd (7.0, 6.8) | 45.5, d |
| | 3 | 4.18, dqd (6.8, 6.7, 6.2) | 48.6, d | 4.27, m | 48.3, d |
| | 4 | 1.16, d (6.7) | 19.7, ^c q | 1.22, d (6.7) | 19.5, q |
| | 5 | 1.10, d (6.9) | 14.6, q | 1.15, d (7.0) | 14.5, q |
| Thr | NH | 7.40, br d (6.8) | | 7.31, m | |
| | 6 | | 169.8, s | | 169.6, s |
| | 7 | 4.45, dd (7.8, 6.4) | 59.2, d | 4.49, dd (7.9, 6.7) | 58.8, d |
| | 8 | 4.02, dq (6.4, 6.2) | 68.8, d | 4.03, m | 68.5, d |
| | 9 | 1.23, d (6.2) | 19.7, ^c q | 1.29, d (6.4) | 19.7, q |
| N-Me-Leu | OH | 3.96, br | | 5.02, ^d br | |
| | NH | 7.12, d (7.8) | | 7.13, d (7.9) | |
| | 10 | | 170.3, s | | 170.3, s |
| | 11 | 4.92, br | 56.7, d | 5.02, br | 56.1, d |
| | 12a | 1.85, m | 36.9, t | 1.89, m | 36.4, t |
| Aba-thn-ca/Ala-thn-ca | 12b | 1.72, ddd (-14, 8.1, 6.2) | | 1.76, ddd (-14.3, 7.9, 6.5) | |
| | 13 | 1.55, m | 25.1, d | 1.59, m | 24.8, d |
| | 14 | 0.95, d (6.6) | 23.2, q | 1.02, d (6.6) | 23.0, q |
| | 15 | 0.90, d (6.5) | 22.1, q | 0.96, d (6.4) | 21.9, q |
| | 16 | 3.15, s | 32.3, q | 3.22, s | 31.6, q |
| | 17 | | 170.4, s | | 170.2, s |
| | 18 | 5.32, ddd (9.5, 9.1, 1.8) | 77.8, d | 5.347, dd (10.4, 10.4) | 77.6, d |
| | 19a | 3.58, dd (-9.9, 9.1) | 33.4, t | 3.71, dd (-10.5, 10.4) | 33.3, t |
| N-Me-Phe-thn-ca | 19b | 3.27, dd (-9.9, 9.5) | | 3.33, dd (-10.5, 10.4) | |
| | 20 | | 178.5, s | | 178.9, s |
| | 21 | 4.64, m | 54.4, d | 4.90, dq (7.5, 7.1) | 48.2, d |
| | 22a | 2.18, m | 25.2, t | 1.65, d (7.1) | 18.0, q |
| | 22b | 1.97, m | | | |
| | 23 | 0.96, t (7.2) | 11.0, q | | |
| | NH | 7.53, d (7.9) | | 7.73, d (7.5) | |
| | 24 | | 171.0, s | | 170.4, s |
| Pro | 25 | 5.30, m | 79.3, d | 5.351, m | 78.8, d |
| | 26a | 3.70, m (2H) | 37.7, t | 3.77, m (2H) | 37.6, t |
| | 26b | | | | |
| | 27 | | 177.2, s | | 177.5, s |
| | 28 | 3.83, dd (9.0, 3.5) | 69.0, d | 3.91, dd (10.1, 3.2) | 68.9, d |
| | 29a | 3.57, dd (-13.9, 9.0) | 35.3, t | 3.65, dd (-13.4, 10.1) | 34.9, t |
| | 29b | 3.44, dd (-13.9, 3.5) | | 3.48, dd (-13.4, 3.2) | |
| | 30 | | 138.2, s | | 138.2, s |
| | 31/35 | 7.35, m | 129.8, d | 7.43, m | 129.8, d |
| | 32/34 | 7.34, m | 128.7, d | 7.36, m | 127.1, d |
| | 33 | 7.25, m | 126.7, d | 7.43, m | 128.6, d |
| 36 | 2.78, s | 39.6, q | 2.81, s | 39.3, q | |
| N-Me-Val | 37 | | 173.0, s | | 172.9, s |
| | 38 | 4.77, dd (7.4, 5.5) | 57.0, d | 4.81, dd (8.4, 4.2) | 57.0, d |
| | 39a | 2.04, m (2H) | 27.5, t | 2.11, m | 27.4, t |
| | 39b | | | 2.06, m | |
| | 40a | 2.12, m | 24.8, t | 2.18, m | 24.6, t |
| | 40b | 1.86, m | | 1.93, m | |
| | 41a | 3.69, m | 47.6, t | 3.76, m | 47.4, t |
| | 41b | 3.60, m | | 3.67, m | |
| Pla | 42 | | 167.8, s | | 168.1, s |
| | 43 | 4.93, d (10.9) | 60.3, d | 4.98, d (10.9) | 60.0, d |
| | 44 | 2.42, dqd (10.9, 6.7, 6.4) | 27.3, d | 2.47, dqd (10.9, 6.6, 6.4) | 27.1, d |
| | 45 | 0.97, d (6.4) | 19.5, q | 1.01, d (6.4) | 19.2, q |
| | 46 | 0.87, d (6.7) | 18.2, q | 0.93, d (6.6) | 17.9, q |
| | 47 | 3.11, s | 30.3, q | 3.20, s | 30.1, q |
| | 48 | | 171.1, s | | 171.0, s |
| | 49 | 5.40, dd (9.9, 3.5) | 72.0, d | 5.40, dd (9.9, 3.0) | 72.0, d |
| | 50a | 3.12, dd (-14.5, 9.9) | 37.2, t | 3.17, dd (-14.3, 9.9) | 37.0, t |
| | 50b | 3.00, dd (-14.5, 3.5) | | 3.06, dd (-14.3, 2.7) | |
| | 51 | | 135.6, s | | 135.7, s |
| | 52/56 | 7.21, m | 129.2, d | 7.27, m | 129.1, d |
| | 53/55 | 7.30, m | 128.6, d | 7.36, m | 128.5, d |
| | 54 | 7.26, m | 127.3, d | 7.32, m | 126.8, d |

^aMultiplicity derived from APT and HMQC spectra. ^bMultiplicity derived from edited HSQC spectrum. ^cThese carbons have the same chemical shift. ^dOH signal assigned by default.




FIGURE 2. Grassyseptolide crystal structures: (a) displacement ellipsoids (50% probability) for the X-ray crystal structure of grassyseptolide B (**2**); (b) overlay of X-ray crystal structures of grassyseptolides A (**1**, magenta) and B (**2**, cyan).

sequences of Maba–Thr–*N*-Me-Leu and Aba–*N*-Me-Phe–thn–ca–Pro–*N*-Me-Val–Pla. A ROESY correlation was present between H-28 and H-38 (*N*-Me-Phe and Pro α -protons, respectively), suggesting that the intervening amide bond was *cis*, in contrast to the corresponding bond in the crystal structures of **1** and **2**. To confirm the complete sequence of **3**, ESIMS/MS studies were carried out using **1** and **2** for comparison (see Figure 3). Analysis of the fragmentation patterns of **1** and **2**, as well as MS/MS/MS of the prominent ions 859.3 and 845.3 (see Figure 3) allowed the assignments shown. We found a dominant continuous series of mainly b ions, resulting from ring-opening at the Pro–*N*-Me-Val amide bond. This is consistent with previous studies of cyclic peptide fragmentation, where only b ions were observed,¹⁸ and it was noted that in some proline-containing molecules, ring opening predominantly occurs at this residue.¹⁹ None of the other possible b ion series were observed. However, the major series resulted from loss of Pla–*N*-Me-Val to give a pseudo c ion (859.3/845.3, see Figure 3), followed by loss of Thr–Maba to give a b ion (641.2/627.2), Pro–*N*-Me-Phe (411.0/397.1), and finally Aba/Ala–thn (241.2/241.1). Compound **3** showed a fragmentation pattern identical to that of both **1** and **2**, and therefore it shares the same sequence.

Attempts to crystallize **3** failed, perhaps because the isolated yield (0.6 mg) was insufficient. Compound **3** was hydrolyzed with 6 N HCl (110 °C, 18 h), and the hydrolyzate

was subjected to chiral HPLC-MS to reveal the presence of *D*-*allo*-Thr, *N*-Me-L-Val, L-Pro, *N*-Me-D-Leu, and L-Pla. Compound **3** was treated with ozone at –78 °C followed by oxidative workup and acid hydrolysis, and then the product was analyzed by chiral HPLC-MS to detect the presence of *D*-Aba. Under these conditions two peaks were observed corresponding to *N*-Me-L-Phe and *N*-Me-D-Phe in the ratio 1.28:1, respectively. More stringent ozonolysis conditions were then used to treat both **1** and **3** (30 min, rt) in order to convert *N*-Me-Phe to *N*-Me-Asp. Analysis of the reaction product of **3** by chiral HPLC-MS again showed the presence of both enantiomers of *N*-Me-Asp in the ratio of 1.22:1 L to *D*. Two peaks in the ratio of 1:1.85 corresponding to *N*-Me-L-Asp and *N*-Me-D-Asp, respectively, were also apparent in the ozonolysis product of **1** under the same conditions. In an attempt to liberate *N*-Me-Phe under milder conditions, leading to less epimerization, we treated both **1** and **3** with RuCl₃/NaIO₄, which in the past has been used both to cleave double bonds and to oxidize thioethers.²⁰ After hydrolysis of the reaction product with 6 N HCl (110 °C, 16 h), chiral HPLC-MS analysis revealed the presence of *N*-Me-L-Phe and *N*-Me-D-Phe in the ratios 1:4.88 for **1** and 3.35:1 for **3**, clearly indicating L-configuration in **3** and *D*-configuration in **1**. The difference in configuration at that position is consistent with NMR chemical shift evidence, as pointed out above. Additionally, compounds **1** and **3** have very different specific rotations ($[\alpha]_D^{20}$ of +78 and +18°, respectively), supporting a difference in configuration. Consistent with previous experience with **1**, both L-cysteic acid and *D*-cysteic acid (Cya) were detected in the ozonolysis product of **3**. Since both enantiomers were observed in a similar ratio when derived from **1** and **3** (~2:1), and also because the ¹H and ¹³C NMR chemical shifts of the thiazoline moiety signals are both much the same as those of **1**, the configuration of both are likely *R* in **3** as well as **1**. Consequently, we conclude that **1** and **3** differ indeed only in the configuration at C-28.

Considering that we isolated two epimers, **1** and **3**, from cyanobacterial extracts, a relevant question is whether the intact molecules can interconvert. This has some precedence, for example, a synthetic analogue of trunkamide A containing L-Phe adjacent to the thiazoline in place of *D*-Phe showed spontaneous epimerization to the natural product.²¹ Likewise, the synthetic 3*S* isomer of lissoclinamide **7** showed conversion to lissoclinamide **7** (see Figure 1b) in the presence of pyridine and CDCl₃ at 60 °C, although the reverse conversion was not observed.²² Using these same conditions we were not able to convert intact **3** to **1** or vice versa, perhaps suggesting that neither are isolation artifacts. A reduced tendency for base-induced interconversion may reflect less overall strain in the macrocycle; compounds **1** and **3** are 31-membered, whereas lissoclinamide **7** and trunkamide A are both 21-membered. The fact that the 28*S* isomer, compound **3**, was isolated in much reduced yield compared with **1** suggests that **3** could be a minor side-product of the biosynthesis of **1** or else is an activated form (vide infra).²³

(20) Plietker, B. *Synthesis* **2005**, 2453–2472.

(21) Salvatella, X.; Caba, J. M.; Albericio, F.; Giralt, E. *J. Org. Chem.* **2003**, *68*, 211–215.

(22) Wipf, P.; Fritch, P. C.; Geib, S. J.; Sefer, A. M. *J. Am. Chem. Soc.* **1998**, *120*, 4105–4112.

(23) Kwan, J. C.; Luesch, H. *Chem. Eur. J.* **2010**, published online ahead of print; DOI: 10.1002/chem.201001562.

(18) Liu, W.-T.; Ng, J.; Meluzzi, D.; Bandeira, N.; Gutierrez, M.; Simmons, T. L.; Schultz, A. W.; Lington, R. G.; Moore, B. S.; Gerwick, W. H.; Pevzner, P. A.; Dorrestein, P. C. *Anal. Chem.* **2009**, *81*, 4200–4209.

(19) Ngoka, L. C. M.; Gross, M. L. *J. Am. Soc. Mass Spectrom.* **1999**, *10*, 732–746.




FIGURE 3. MS/MS fragmentation data for grassypeptolides A–C (1–3).

Molecular Modeling of Grassypeptolide C (3). To further explore the potential conformational differences between **1**, **2**, and **3**, we carried out molecular modeling of **3**. Apart from the differences in chemical shifts already noted, the NMR spectra of **1** and **3** are similar, which therefore suggested a fairly similar conformation for both compounds. In particular, the two $^3J_{\text{NH}-\alpha\text{H}}$ values that could be measured in **3** (indicative of Φ angles)²⁴ had almost the same values in **1**. Therefore, the same ROESY distances and angle constraints previously used for modeling of **1**¹² were used. Most of the ROESY correlations observed for **1** were also seen for **3** (see Table 2, common correlations shown in bold), but four extra interresidue correlations were added for modeling purposes (see Table 2, shown in red). In addition, the *N*-Me-Phe–Pro amide bond was set to *cis* as previously noted. As with modeling for **1**, 10 random structures were subjected to distance geometry followed by simulated annealing and then constrained molecular dynamics (see Experimental Section). This resulted in two conformational families; however, one clearly had higher calculated energies and a larger number of constraint violations (3 structures, average 61.2 kcal/mol and 8 violations; see Table S4–S14 and Figure S1, Supporting Information). The other family was all within 1 Å rmsd of the lowest energy conformation and showed closely related

backbone conformations (7 structures, average 35.1 kcal/mol and 2.3 constraint violations; see Figure 4a and Table S4). Interestingly, this family contained two orientations of the *N*-Me-Phe side chain, with H-28 either pointing into the center of the macrocycle or away from it. The interconversion of these two forms would have resulted from a rotation of the C27–C28 bond (see Figure 4b). The backbone conformation for the lower energy conformational family is also like that of the crystal structure of **1** (see Figure 4c).

Antiproliferative Activity. Previously, we found that **1** was cytotoxic against a number of cancer cell lines with IC_{50} s in the low micromolar range.¹² Compounds **2** and **3** were tested alongside **1** in two cell lines, HT29 (colorectal adenocarcinoma) and HeLa (cervical carcinoma; see Table 3). Surprisingly, **3** was 16–23 times more potent than **1** and 65-fold more potent than **2**. Presumably this is due to differences in conformation and suggests that the region around the *N*-Me-Phe is crucial to cytotoxicity. Interestingly, the synthetic 3*S*-isomer of lissoclinamide **7** (Figure 1b) was also found to be more potent than the isolated natural compound in some cell lines.²² To test if the antiproliferative effects were mediated by stage specific cell cycle arrest, we investigated the effect of both **1** and **3** on cell cycle in HT29 cells (see Figure 5) using FACS-based DNA content analysis. Both compounds exhibited G1 arrest at lower concentrations, followed by G2/M arrest at higher concentrations, with **3** showing these effects at lower concentrations than **1** (see Figure 5). An increase in

(24) Vögeli, B.; Ying, J.; Grishaev, A.; Bax, A. *J. Am. Chem. Soc.* **2007**, *129*, 9377–9385.

TABLE 2. NMR Spectral Data for Grassypeptolide C (3) in CDCl₃ at 600 MHz

| | C/H no. | δ_{H} (J in Hz) | δ_{C}^a | $^1\text{H}-^1\text{H COSY}^b$ | HMBC ^c | ROESY ^{d,e,f} | |
|------------|-----------------|-------------------------------|------------------------|---|--------------------|---|--|
| Maba | 1 | | 172.6, s | | | | |
| | 2 | 2.48, qd (6.9, 6.6) | 45.7, d | H-3, H ₃ -5 | 1, 3, 4, 5 | H-3, H₃-4, H₃-5 | |
| | 3 | 4.22, m | 48.7, d | H-2, H ₃ -4, NH | 1, 2, 4, 5, 6 | H-2, H₃-4, H₃-5 | |
| | 4 | 1.18, d (6.9) | 19.9, q | H-3 | 2, 3 | H-2, H-3 | |
| | 5 | 1.11, d (6.9) | 14.6, q | H-2 | 1, 2, 3 | H-2, H-3 | |
| Thr | NH | 7.65, br | | H-3 | | | |
| | 6 | | 169.5, s | | | | |
| | 7 | 4.44, dd (6.9, 6.0) | 59.2, d | H-8, NH | 6, 8, 9, 10 | H₃-9, H₃-16, NH | |
| | 8 | 3.99, m | 69.2, d | H-7, H ₃ -9 | 6 (w) ^f | H₃-9, NH | |
| | 9 | 1.21, d (6.3) | 19.6, q | H-8 | 7, 8 | H-7, H-8, H₃-16 | |
| N-Me-Leu | OH | | | | | | |
| | NH | 6.94, d (7.4) | | H-7 | 10 | H-7, H-8, H-12b | |
| | 10 | | 170.6, s | | | | |
| | 11 | 4.70, br | 57.6, d | H-12a, H-12b | | H₃-15, H₃-16 | |
| | 12a | 1.92, m | 37.3, t | H-11, H-12b, H-13 | | H-12b, H-13, H₃-14 | |
| | 12b | 1.66, ddd (-14.3, 8.5, 5.8) | | H-11, H-12a, H-13 | 10, 11, 13, 14, 15 | H-12a, H₃-15, H₃-16, NH (Thr) | |
| | 13 | 1.56, m | 25.2, d | H-12a (w), ^g H-12b, H ₃ -14, H ₃ -15 | | H-12a, H₃-14, H₃-16 | |
| | 14 | 0.955, m | 23.2, q | H-13 | 12, 13, 15 | H-12a, H-13, H₃-16 | |
| Aba-thn-ca | 15 | 0.92, d (6.7) | 22.1, q | H-13 | 12, 13, 14 | H-11, H-12b | |
| | 16 | 3.171, s | 33.1, q | | 11, 17 | H-7, H₃-9, H-11, H-12b, H-13, H₃-14, H-18, H-21 | |
| | 17 | | 170.3, s | | | | |
| | 18 | 5.27, dd (9.9, 1.6) | 78.3, d | H-19a, H-19b | 17, 20 | H₃-16, H-19b | |
| | 19a | 3.60, dd (-10.2, 1.6) | 33.2, t | H-18, H-19b | 17 | H-19b, H-22b | |
| | 19b | 3.28, dd (-10.2, 9.9) | | H-18, H-19a | 17, 20 | H-18, H-19a | |
| | 20 | | 177.8, s | | | | |
| | 21 | 4.55, m | 54.6, d | H-22a (w), ^g H-22b, NH | | H₃-16, H-22a, H-22b (w),^g H₃-23, H-25^f, NH | |
| | 22a | 2.12, m | 25.4, t | H-21 (w), ^g H-22b, H ₃ -23 | | H-21, H-22b, H₃-23 | |
| | 22b | 1.84, m | | H-21, H-22a, H ₃ -23 | 21 | H-19a, H-21, H-22a, H₃-23, NH | |
| | 23 | 0.94, m | 11.0, q | H-22a, H-22b | 21 | H-22a, H-22b, NH | |
| | NH | 7.12, d (7.6) | | H-21 | 21, 22, 24 | H-21, H-22b, H₃-23, H-25, H-28 | |
| | N-Me-Phe-thn-ca | 24 | | 171.7, s | | | |
| | | 25 | 5.03, dd (10.2, 3.0) | 78.1, d | H-26a, H-26b | 24, 27 | H-21^f H-26a, H-26b, NH (Aba) |
| | | 26a | 3.67, dd (-11.1, 3.0) | 37.4, t | H-25, H-26b | 24, 27 | H-25 |
| | | 26b | 3.61, dd (-11.1, 10.2) | | H-25, H-26a | 24, 25 | H-25 |
| 27 | | | 177.2, s | | | | |
| 28 | | 5.48, dd (9.1, 7.8) | 59.2, d | H-29a, H-29b | 26, 27, 30, 36, 37 | H-29a, H-31/35, H₃-36, H-38, NH (Aba) | |
| 29a | | 3.21, m | 36.3, t | H-28, H-29b | 27, 28, 30, 31/35 | H-28, H-31/35 | |
| 29b | | 3.16, m | | H-28, H-29a | 27, 28, 30, 31/35 | H-31/35 | |
| 30 | | | 135.6, s | | | | |
| 31/35 | | 7.23, m | 128.8, d | H-32/34 | 29, 30, 31/35 | H-28, H-29a, H-29b | |
| 32/34 | | 7.33, m | 129.0, d | H-31/35, H-33 | | | |
| 33 | | 7.29, m | 127.3, d | H-32/34 | | | |
| Pro | 36 | 3.169, s | 30.7, q | | 37 | H-28, H-38, H-39a, H-39b, H-40b | |
| | 37 | | 173.2, s | | | | |
| | 38 | 4.80, dd (8.7, 5.0) | 57.7, d | H-39a, H-39b | 37, 39, 40, 41 | H-28, H₃-36, H-39a, H-40a, H-40b, H-41a (w)^g | |
| | 39a | 2.19, m | 27.9, t | H-38, H-39b, H-40a, H-40b | | H₃-36, H-38, H-39b, H-40b | |
| | 39b | 1.93, m | | H-38, H-39a, H-40a, H-40b | 37, 38, 40, 41 | H₃-36, H-39a, H-41a | |
| | 40a | 1.98, m | 24.9, t | H-39a, H-39b, H-40b, H-41a, H-41b | | H-38, H-40b, H-41b | |
| | 40b | 1.84, m | | H-39a, H-39b, H-40a, H-41a, H-41b | 39, 41 | H₃-36, H-38, H-39a, H-40a, H-41a, H-41b | |
| | 41a | 3.97, m | 48.1, t | H-40a, H-40b, H-41b | 39, 40 | H-38 (w),^g H-39b, H-40b, H-43 | |
| | 41b | 3.51, m | | H-40a, H-40b, H-41a | 39, 40 | H-40a, H-40b, H-43 | |
| | N-Me-Val | 42 | | 168.5, s | | | |
| 43 | | 4.95, d (11.1) | 60.1, d | H-44 | 42, 44, 45, 47, 48 | H-41a, H-41b, H-44, H₃-45, H₃-46, H₃-47 | |
| 44 | | 2.30, m | 27.3, d | H-43, H ₃ -45, H ₃ -46 | 43, 46 | H-43, H₃-45, H₃-46, H₃-47 | |
| 45 | | 0.960, m | 19.2, q | H-44 | 43, 44, 46 | H-43, H-44 | |
| 46 | | 0.88, d (6.5) | 18.3, q | H-44 | 43, 44, 45 | H-43, H-44, H₃-47 | |
| 47 | | 3.11, s | 30.1, q | | 43, 48 | H-43, H-44, H₃-46, H-49 | |
| 48 | | | 171.2, s | | | | |
| 49 | | 5.33, dd (9.5, 3.2) | 72.6, d | H-50a, H-50b | 50, 51 | H₃-47, H-50b, H-52/56 | |
| Pla | 50a | 3.06, dd (-14.4, 9.5) | 37.0, t | H-49, H-50b | 48, 49, 51, 52/56 | H-52/56 | |
| | 50b | 3.00, dd (-14.4, 3.2) | | H-49, H-50a | 48, 51, 52/56 | H-49, H-52/56 | |
| | 51 | | 135.8, s | | | | |
| | 52/56 | 7.20, m | 129.2, d | H-53/55 | 50, 53/55 | H-49, H-50a, H-50b | |
| | 53/55 | 7.31, m | 128.7, d | H-52/55, H-54 | 51 | | |
| | 54 | 7.29, m | 127.3, d | H-53/55 | | | |

^aMultiplicity derived from edited HSQC spectrum. ^bCorrelations to NH protons in the same unit unless otherwise indicated. ^cProtons showing long-range correlation with indicated carbon. ^dCorrelations also observed in the ROESY spectrum of grassypeptolide A (1) in CDCl₃ are shown in bold, and correlations that were used as extra constraints in molecular modeling are shown in red. ^e(w) indicates a weak correlation. ^fThis correlation was previously observed in the ROESY spectrum of grassypeptolide A (1) in DMSO-*d*₆ but not the ROESY spectrum in CDCl₃.

apoptotic sub-G1 or “sub-G2” populations is also seen. It is interesting that 3, the most active of the series, was recovered as the most minor component from the cyanobacterial extract. This could be an indication that 1 requires activation by

epimerization, possibly as a strategy for self-resistance by the producing organism.

Metal Binding. Cyclic peptides that have tandem thiazole/oxazole or thiazoline/oxazoline rings, for example, patellamides




FIGURE 4. Molecular modeling of grassypeptolide C (**3**): (a) lower-energy conformational family of models of grassypeptolide C (**3**); (b) select models showing two possible orientations of the *N*-Me-Phe side chain (lowest-energy examples of **3** (green); (c) comparison of lowest energy conformation of **3** (green) and the crystal structure of **1** (purple), showing *N*-Me-Phe α -protons to illustrate configuration at this center and the amide bond that is *trans* and *cis* in **1** and **3**, respectively.

TABLE 3. IC₅₀ Values for Cytotoxicity Exhibited by Grassypeptolides A–C (**1–3**) against Two Cancer Cell Lines

| cell line | grassypeptolide A (1) | grassypeptolide B (2) | grassypeptolide C (3) |
|-----------|--------------------------------|--------------------------------|--------------------------------|
| HT29 | 1.22 μ M | 4.97 μ M | 76.7 nM |
| HeLa | 1.01 μ M | 2.93 μ M | 44.6 nM |

A and C and ascidiacyclamide (see Figure 6), have been shown to bind to metals such as Cu²⁺ and Zn²⁺.^{25–27} In the crystal structure of ascidiacyclamide,²⁷ the molecule is complexed with two Cu²⁺ ions bridged by a carbonate anion. Each Cu²⁺ is coordinated to one thiazole, one oxazoline, and the intervening deprotonated amide (see Figure 6), which has been termed a “TAO” domain, and is also thought to bind Cu²⁺ in the patellamides.^{28,29} Additionally, a nonspecific cytotoxic metal chelator (tachpyridine) has been shown to cause G2/M phase cell-cycle arrest in HeLa cells.³⁰ Since compounds **1–3** also promoted G2/M cell cycle arrest and contained a motif comprising two thiazolines and an intervening amide (similar to TAO), we investigated the binding of **1** to Cu²⁺ and Zn²⁺.

The circular dichroism spectrum of **1** revealed positive maxima at 218, 230, and 253 nm (see Figure 7). Previously the CD spectra of patellamides A and C, lissoclinamides 9 and 10, and ulithiacyclamide had been investigated.^{26,31} The near-UV CD maximum at 253 nm could be due to the aromatic *N*-Me-Phe and Pla residues, while the far-UV maximum at 218 nm is similar to that observed in the random coil conformation of poly(Lys).³² The remaining maximum at 230 nm could be attributed to the tight turn at *N*-Me-Phe-thn-ca observed in the solid state and solution structures of **1**. The CD spectra of β -turns are fairly variable,³³ but some examples exist with positive maxima near 230 nm. Upon addition of one equivalent of Cu²⁺, the shape of the CD spectrum of **1** changed (see Figure 7b), indicating that the binding of Cu²⁺ to **1** occurs, and that it is accompanied by a slight change in conformation. A second equivalent of Cu²⁺ did not cause a further change, indicating a 1:1 stoichiometry. Addition of 1 equiv of Zn²⁺ to **1** also brought about a slight change in the CD spectrum (see Figure 7c and d). While Cu²⁺ caused both positive and negative changes in the CD spectrum of **1** (see Figure 7b), Zn²⁺ generated only positive changes (see Figure 7d), perhaps indicating different conformations for the resulting complexes. These results are qualitatively reminiscent of the changes in CD spectrum seen when Cu²⁺ and Zn²⁺ are added to lissoclinamide 10,

(25) Bertram, A.; Pattenden, G. *Nat. Prod. Rep.* **2007**, *24*, 18–30.
 (26) Morris, L. A.; Jaspars, M.; Kettenes-van den Bosch, J. J.; Versluis, K.; Heck, A. J. R.; Kelly, S. M.; Price, N. C. *Tetrahedron* **2001**, *57*, 3185–3197.

(27) van den Brenk, A. L.; Byriel, K. A.; Fairlie, D. P.; Gahan, L. R.; Hanson, G. R.; Hawkins, C. J.; Jones, A.; Kennard, C. H. L.; Mobaraki, B.; Murray, K. S. *Inorg. Chem.* **1994**, *33*, 3549–3557.

(28) Morris, L. A.; Milne, B. F.; Thompson, G. S.; Jaspars, M. *J. Chem. Soc., Perkin Trans. 2* **2002**, 1072–1075.

(29) Latifi, R.; Bagherzadeh, M.; Milne, B. F.; Jaspars, M.; de Visser, S. P. *J. Inorg. Biochem.* **2008**, *102*, 2171–2178.

(30) Turner, J.; Koumenis, C.; Kute, T. E.; Planalp, R. P.; Brechbiel, M. W.; Beardsley, D.; Cody, B.; Brown, K. D.; Torti, F. M.; Torti, S. V. *Blood* **2005**, *106*, 3191–3199.

(31) Morris, L. A.; Milne, B. F.; Jaspars, M.; Kettenes-van den Bosch, J. J.; Versluis, K.; Heck, A. J. R.; Kelly, S. M.; Price, N. C. *Tetrahedron* **2001**, *57*, 3199–3207.

(32) Sreerama, N.; Woody, R. W. In *Circular Dichroism: Principles and Applications*, 2nd ed.; Berova, N.; Nakanishi, K.; Woody, R. W., Eds.; Wiley-VCH: New York, 2000; pp 601–620.

(33) Perczel, A.; Hollósi, M. In *Circular Dichroism and the Conformational Analysis of Biomolecules*; Fasman, G. D., Ed.; Plenum Press: New York, 1996; pp 285–380.






FIGURE 5. Cell cycle analysis of HT29 cells treated with grassypeptolides A (1) and C (3) for 24 h. Taxol served as a positive control for G2 arrest.



Patellamide A $R_1 = R_2 = iPr$, $R_3 = H$, $R_4 = Et$

Patellamide C $R_1 = Bz$, $R_2 = R_3 = R_4 = Me$



Bis-Cu(II)-ascidiacyclamide complex

FIGURE 6. Structures of patellamides A and C and the structure of the bis-Cu(II)-ascidiacyclamide complex, with TAQ domains in red.

a 21-membered cyclic peptide that contains two thiazolines, an oxazoline and a proline.³¹ In this compound, Cu^{2+} causes

both positive and negative changes in the CD spectrum with two isobestic points, whereas Zn^{2+} causes only a negative change. Unfortunately, there were insufficient amounts of **3** to obtain a CD spectrum; however, we were able to obtain evidence of both Cu^{2+} and Zn^{2+} adducts by MS for both **1** and **3** (see Figure 8). Both compounds exhibited $[M - H + Cu]^+$ ions with the expected isotope distribution, as well as several Zn^{2+} adducts ($[M + Zn]^{2+}$, $[M - H + Zn]^+$, and $[M + ZnCl]^+$).

Conclusions

We have described two new cytotoxic cyclic depsipeptides, grassypeptolides B (2) and C (3). Compounds 1–3 show a natural structure–activity relationship. While the replacement of D-Aba (1) with D-Ala (2) only slightly reduced potency, inversion of *N*-Me-D-Phe (1) to *N*-Me-L-Phe (3) lowered the IC_{50} by 16–23-fold (see Table 3). Like the thiazole- and oxazoline-containing cyclic peptides patellamides A and C and ulithiacyclamide, compounds 1 and 3 can bind to metals. This activity may be a potential mechanism for cytotoxicity in mammalian cells, as many classes of enzymes are known to rely on metal cofactors. For example, ribonucleotide reductase (RR) requires iron for catalysis of the conversion of ribonucleotides to deoxyribonucleotides, the precursors needed for the synthesis of DNA during S phase of the cell cycle. Iron depletion by exogenous chelators therefore causes cell cycle arrest at the G_1/S phase,³⁴ through

(34) Le, N. T. V.; Richardson, D. R. *Biochim. Biophys. Acta* **2002**, 1603, 31–46.




FIGURE 7. Circular dichroism spectra of grassypeptolide A (**1**) in the presence and absence of Cu^{2+} and Zn^{2+} : (a) CD spectra of **1** alone and after addition of 1 and 2 equiv of Cu^{2+} to **1**; (b) differences induced in the CD spectrum of **1** by addition of Cu^{2+} ; (c) CD spectra of **1** alone and after addition of 1 or 2 equiv of Zn^{2+} ; (d) differences induced in the CD spectrum of **1** by addition of Zn^{2+} .

inhibition of RR and other mechanisms.³⁵ However, metal chelators have been shown to induce G₂/M cell cycle arrest under some conditions, such as desferrioxamine³⁶ and tachpyridine.³⁰ The latter was shown to mediate this effect through activation of CHK1 and CHK2, potentially through ataxia-telangiectasia-mutated and *Rad3*-related kinase (ATR). Another potential target for metal chelators is Cu/Zn superoxide dismutase (SOD1),^{37,38} which protects cells from superoxide radicals produced during normal metabolism and especially at times of oxidative stress. Inhibition of SOD1 can lead to buildup of reactive oxygen species (ROS), which can result in activation of both G1 and G2 checkpoint functions through the ataxia telangiectasia gene product (ATM).³⁹ Our cell cycle data for **1** and **3**, where a degree of both G1 and G2/M phase arrest is seen, is consistent with these compounds' abilities to bind metals. Compound **1** has a low micromolar IC₅₀ in a number of cancer cell lines, which is a potency similar to that of desferrioxamine⁴⁰ and tachpyridine.³⁰ Compound **3** was more potent, and this could be due to an increased affinity for metals. However, it should be noted that the direct involvement of metals in the cytotoxicity of **1**–**3** was not demonstrated, and metal-independent major pleiotropic mechanisms of action for these compounds may exist. In light of previous examples of intricate protection/activation strategies in natural products,²³ a potential hypothesis is that compound **3** may represent an activated form of **1**, and this process may constitute a self-resistance strategy by the producing organism. We were unable to convert **1** to **3** under basic conditions, but this does not exclude conversion by a specific enzyme. Compound **3** could also be a minor byproduct of the biosynthesis of **1**, or it could be the result of a modified pathway in a minority of cells in the collected material.

Experimental Section

General Experimental Methods. NMR spectra for **2** and **3** were acquired on an NMR spectrometer using a 1-mm triple-resonance high-temperature superconducting cryogenic probe.⁴¹ Spectra were referenced to the residual solvent signals of CDCl_3 [$\delta_{\text{H/C}}$ 7.26/77.0]. Edited HSQC experiments were optimized for 145 Hz, and HMBC experiments were optimized for 7 Hz.

Extraction and Isolation. Samples of *L. confervoides* were collected off Grassy Key, Florida, on May 26, 2004, and fractionated as previously described.¹² Samples of the same species were collected off Key Largo, Florida, on May 8, 2003, and fractionated as previously described.¹⁷ Silica gel fractions from both extracts eluting with *i*-PrOH and MeOH were subjected to preparative HPLC [column, Luna 10 μm C18(2) 100A AXI, 100 mm \times 21.2 mm, 10.0 mL/min, UV detection at 220 and 254 nm] using a MeOH–H₂O linear gradient (60–100% MeOH over 30 min, then 100% MeOH for 5 min). From each fraction, impure **2** eluted at t_{R} = 21.5 min and **1** eluted at t_{R} = 22.1 (14.5 mg). The collected peaks appeared the same by ¹H NMR and so were combined before being subjected to another round of HPLC purification [column, YMC-Pack ODS-AQ, 250 mm \times 10 mm, 2.0 mL/min; PDA detection, 190–500 nm] using a linear MeOH–H₂O gradient (60–97.5% MeOH over 28 min, then 97.5% MeOH for 20 min) to give **2** (1.7 mg) at t_{R} = 32.7 min.

The 20:80 *i*-PrOH/ CH_2Cl_2 fraction from the silica column of the extract of the Grassy Key material was subjected to reversed-phase HPLC [column, YMC-Pack ODS-AQ, 250 mm \times 10 mm, 2.0 mL/min; PDA detection, 190–500 nm], using a linear MeOH–H₂O gradient (60–100% MeOH over 30 min, then 100% MeOH for 20 min), to furnish **3** (0.6 mg) and **1** (1.9 mg) at t_{R} 31.4 and 33.3 min, respectively.

Reisolation of Grassypeptolides. Samples of *L. confervoides* collected off Big Pine Shoals, Florida, on May 30, 2009, were extracted as previously described.¹² The nonpolar extract was subjected to solvent partitioning to give hexanes-, butanol-, and water-soluble fractions. The butanol-soluble portion was directly fractionated over silica gel eluting with increasing amounts of *i*-PrOH in CH_2Cl_2 . Fractions eluted with 20% and 50% *i*-PrOH/ CH_2Cl_2 (15.8 mg and 32.2 mg, respectively) consisted of mixtures of grassypeptolides A (**1**), B (**2**), and C (**3**).

(35) Yu, Y.; Kovacevic, Z.; Richardson, D. R. *Cell Cycle* **2007**, *6*, 1982–1994.

(36) Renton, F. J.; Jeitner, T. M. *Biochem. Pharmacol.* **1996**, *51*, 1553–1561.

(37) Huang, P.; Feng, L.; Oldham, E. A.; Keating, M. J.; Plunkett, W. *Nature* **2000**, *407*, 390–395.

(38) Juarez, J. C.; Betancourt, O.; Pirie-Shepherd, S. R.; Guan, X.; Price, M. L.; Shaw, D. E.; Mazar, A. P.; Doñate, D. *Clin. Cancer Res.* **2006**, *12*, 4974–4982.

(39) Shackelford, R. E.; Innes, C. L.; Sieber, S. O.; Heinloth, A. N.; Leadon, S. A.; Paules, R. S. *J. Biol. Chem.* **2001**, *276*, 21951–21959.

(40) Rodriguez-Lucena, D.; Gaboriau, F.; Rivault, F.; Schalk, I. J.; Lescoat, G.; Mislin, G. L. A. *Bioorg. Med. Chem.* **2010**, *18*, 689–695.

(41) Brey, W. W.; Edison, A. S.; Nast, R. E.; Rocca, J. R.; Saha, S.; Withers, R. S. *J. Magn. Reson.* **2006**, *179*, 290–293.




FIGURE 8. (a) Cu^{2+} and Zn^{2+} adducts observed for **1**; (b) Cu^{2+} and Zn^{2+} adducts observed for **3**; (c) calculated isotope patterns for the observed metal adducts.

Each fraction was subjected to repetitive semipreparative HPLC [column, Synergi Hydro-RP 4 μm 80A, 250 mm \times 10.0 mm or Luna Phenyl-Hexyl 5 μm 100A, 250 mm \times 10.0 mm, 2.0 mL/min, UV detection at 220 and 240 nm] using a MeOH–H₂O linear gradient (60–100% MeOH over 30 min, then 100% MeOH for 20 min or 80–100% MeOH over 20 min, then 100% MeOH for 10 min) to give grassypeptolides A (**1**, 3.8 mg), B (**2**, 0.4 mg), and C (**3**, 0.6 mg), confirmed by ¹H NMR and MS analysis.

Grassypeptolide B (2). Colorless amorphous solid; [α]_D²⁰ +109; HRESI/APCIMS m/z [M + Na]⁺ 1110.5115 (calcd for C₅₅H₇₇N₉O₁₀S₂Na, 1110.5133), [M + H]⁺ 1088.5298 (calcd for C₅₅H₇₈N₉O₁₀S₂, 1088.5313); UV (CH₂Cl₂) λ_{max} (log ϵ) 224 (3.20), 250 (sh, 2.80), 280 (sh, 2.58); IR (film) ν_{max} 3306 (br), 3027 (w), 2921, 2851, 2361 (w), 1731, 1641, 1531, 1453, 1266, 1225, 1160, 1122, 1085, 1026, 967, 913 cm⁻¹; ¹H NMR, COSY, edited HSQC, HMBC and ROESY, see Table 1 and Table S1, Supporting Information.

Grassypeptolide C (3). Colorless amorphous solid; [α]_D²⁰ +18; HRESI/APCIMS m/z [M + Na]⁺ 1124.5299 (calcd for

C₅₆H₇₉N₉O₁₀S₂Na, 1124.5289), [M + H]⁺ 1102.5428 (calcd for C₅₆H₈₀N₉O₁₀S₂, 1102.5470); UV (CH₂Cl₂) λ_{max} (log ϵ) 224 (3.82), 260 (3.41); IR (film) ν_{max} 3419 (br), 3056, 2961, 2920, 2851, 2306, 2125, 1750, 1640, 1515, 1456, 1265, 1030, 895 cm⁻¹; ¹H NMR, COSY, edited HSQC, HMBC and ROESY, see Table 2 and Supporting Information.

X-ray Crystallography of Grassypeptolide B (2). The entire isolated yield of **2** was dissolved in a small amount of filtered CH₂Cl₂, and then MeOH was added, followed by H₂O until the saturation point was reached. The solution was left to slowly evaporate at rt for 10 days to yield needle-shaped crystals. Data were collected at 173 K on an X-ray diffractometer equipped with a CCD area detector and a graphite monochromator utilizing Mo K α radiation ($\lambda = 0.71073$ Å). Cell parameters were refined using up to 8192 reflections. A full sphere of data (1850 frames) was collected using the ω -scan method (0.3° frame width). The first 50 frames were remeasured at the end of data collection to monitor instrument and crystal stability (maximum correction on I was < 1%). Absorption corrections by integration were applied on the basis of measured indexed crystal faces.

The structure was solved by the Direct Methods in SHELXTL6 and refined using full-matrix least-squares. The non-H atoms were treated anisotropically, whereas the hydrogen atoms were calculated in ideal positions and were riding on their respective carbon atoms. In addition to the molecule, there is a methanol and water molecule in the asymmetric unit. They are both disordered and were refined in two parts with their site occupation factors dependently refined. A total of 730 parameters were refined in the final cycle of refinement using 3804 reflections with $I > 2\sigma(I)$ to yield R₁ and wR₂ of 5.71% and 8.84%, respectively. Refinement was performed using F².

Ozonolysis and Acid Hydrolysis of Grassypeptolide C (3). A portion (50 μg) of **3** was subjected to acid hydrolysis (6 N HCl, 110 °C, 18 h) and then evaporated to dryness. The sample was reconstituted in 100 μL of H₂O and subjected to chiral HPLC analysis [column, Chirobiotic TAG (4.6 mm \times 250 mm), Supelco; solvent, MeOH–10 mM NH₄OAc (40:60 pH 5.39); flow rate, 0.5 mL/min; detection by ESIMS in positive ion mode (MRM scan)]. D-*allo*-Thr, N-Me-L-Val, L-Pro, and N-Me-D-Leu eluted at $t_{\text{R}} = 12.6, 13.1, 14.8,$ and 112 min, respectively. The retention times (t_{R} , min; MRM ion pair, parent \rightarrow product) of the authentic amino acids were as follows: L-Thr (8.0; 120 \rightarrow 74), L-*allo*-Thr (8.6), D-Thr (9.5), D-*allo*-Thr (12.6), N-Me-L-Val (13.1; 132 \rightarrow 86), N-Me-D-Val (40.4), L-Pro (14.8; 116 \rightarrow 71), D-Pro (41.9), N-Me-L-Leu (16.2, 146 \rightarrow 100), N-Me-D-Leu (112). Compound-dependent MS parameters were as follows: Thr, DP 28, EP 9, CEP 5, CE 14, CXP 3.5; N-Me-Val, DP 37, EP 6, CEP 12, CE 16, CXP 3; Pro, DP 36, EP 10, CEP 8, CE 22, CXP 2.3; N-Me-Leu, DP 35, EP 6, CEP 10, CE 17, CXP 3. Source-dependent MS parameters were as follows: CUR 50, CAD medium, IS 5500, TEM 750, GS1 70, GS2 70. L-Pla was detected with different conditions [column, Chirobiotic TAG (4.6 mm \times 250 mm), Supelco; solvent, MeOH–H₂O (both with 10 mM NH₄OAc, pH 5.43); flow rate, 0.5 mL/min; detection by ESIMS in negative ion mode (MRM scan)], at $t_{\text{R}} = 10.6$. The retention times (t_{R} , min; MRM ion pair, parent \rightarrow product) of the authentic amino acids were as follows: L-Pla (10.6, 165 \rightarrow 147), D-Pla (11.5). The assignment of L-Pla was confirmed by co-injection with both authentic standards. Compound-dependent MS parameters were as follows: DP -37, EP -3, CEP -9, CE -17, CXP -2.8. Source-dependent MS parameters were as follows: CUR 50, CAD high, IS -4500, TEM 750, GS1 70, GS2 70.

Another portion of **3** (50 μg) in 3 mL of CH₂Cl₂ was cooled to -78 °C. Ozone was bubbled through the solution for 30 min, which was then allowed to reach room temperature and evaporated to dryness. The residue was treated with H₂O₂/HCOOH (15% w/v and 50% v/v in H₂O, respectively, 70 °C, 20 min),

evaporated to dryness, and reconstituted in 100 μ L of H₂O. Analysis by chiral HPLC [column, Chirobiotic TAG (4.6 \times 250 mm), Supelco; solvent, MeOH–10 mM NH₄OAc (40:60, pH 5.39); flow rate, 0.5 mL/min; detection by ESIMS in positive ion mode (MRM scan)], revealed the presence of D-Aba at t_R = 15.4, but both *N*-Me-L-Phe and *N*-Me-D-Phe were detected at t_R = 25.3 and 47.3 min, respectively, in the ratio 1.28:1. The retention times (t_R , min; MRM ion pair, parent \rightarrow product) of the authentic amino acids were as follows: L-Aba (9.1, 104 \rightarrow 58), D-Aba (15.4), *N*-Me-L-Phe (25.3, 180 \rightarrow 134), *N*-Me-D-Phe (47.3). Compound-dependent MS parameters were as follows: Aba, DP 41, EP 2, CEP 8, CE 14, CXP 2.3; *N*-Me-Phe, DP 30, EP 10, CEP 13, CE 20, CXP 3. Source-dependent MS parameters were as follows: CUR 50, CAD medium, IS 5500, TEM 750, GS1 70, GS2 70.

Samples of both **1** and **3** (50 μ g each) were subjected to ozonolysis at room temperature for 30 min followed by oxidative workup and then subjected to chiral HPLC analysis [column, Chirobiotic TAG (4.6 mm \times 250 mm), Supelco; solvent, MeOH–10 mM NH₄OAc (30:70, pH 5.14); flow rate, 0.5 mL/min; detection by ESIMS in negative ion mode (MRM scan)]. For the ozonolysis product of **3**, both *N*-Me-L-Asp and *N*-Me-D-Asp were detected at t_R = 6.6 and 10.6 min, respectively, in the ratio of 1.22:1. For the ozonolysis product of **1**, the ratio was 1:1.85. The retention times (t_R , min; MRM ion pair, parent \rightarrow product) of the authentic amino acids were as follows: *N*-Me-L-Asp (6.6, 146 \rightarrow 102), *N*-Me-D-Asp (10.6). Compound-dependent MS parameters were as follows: DP –33, EP –4.5, CEP –14, CE –18, CXP –5. Source-dependent MS conditions were as follows: CUR 50, CAD high, IS –4500, TEM 750, GS1 70, GS2 70. The ozonolysis product of **3** was also examined under different chiral HPLC conditions [column, Chirex phase 3126 (D) (4.6 mm \times 250 mm), Phenomenex; solvent, 2 mM CuSO₄–MeCN (97.5:2.5); flow rate, 0.8 mL/min; UV detection at 254 nm], to confirm the presence of D-*allo*-Thr, *N*-Me-L-Val, L-Pro and D-Aba at t_R = 14.5, 16.3, 17.4, and 21.0, respectively. In addition, both L- and D-Cya were detected at t_R = 19.8 and 23.7, respectively, consistent with previous results for **1** (ratio \sim 2:1).¹² The retention times (t_R , min) of the authentic standards were as follows: L-Thr (10.3), D-Thr (11.6), L-*allo*-Thr (13.9), D-*allo*-Thr (14.5), L-Aba (15.0), D-Aba (21.0), *N*-Me-L-Val (16.3), *N*-Me-D-Val (22.2), L-Pro (17.4), D-Pro (33.6), L-Cya (19.8), D-Cya (23.7).

Thiazoline Cleavage and Oxidation. Both **1** and **3** were treated with RuCl₃/NaIO₄ using the procedure of Jayaraman et al.,⁴² with minor differences. Portions of both compounds (100 μ g of **1** and 200 μ g of **3**) were dissolved in CH₃CN/CCl₄/H₂O (2:2:3, 150 μ L total). To this was added powdered NaIO₄ (3 equiv) followed by RuCl₃ (0.7 mg), and the reactions were stirred at rt for 1 h. The reaction mixtures were then diluted with water and extracted with CH₂Cl₂. The combined CH₂Cl₂ fractions were dried under N₂ and then treated with 6 N HCl at 110 $^{\circ}$ C for 16 h and evaporated to dryness. The resulting hydrolysates were subjected to chiral HPLC analysis [column, Chirobiotic TAG (4.6 mm \times 250 mm), Supelco; solvent, MeOH–10 mM NH₄OAc (40:60, pH 5.39); flow rate, 0.5 mL/min; detection by ESIMS in positive ion mode (MRM scan)]. For **1**, both *N*-Me-L-Phe and *N*-Me-D-Phe were detected at t_R = 25.3 and 47.3 min, respectively, in the ratio 1:4.88. For **3**, the ratio was reversed, with *N*-Me-L-Phe and *N*-Me-D-Phe detected in the ratio 3.35:1. The retention times (t_R , min; MRM ion pair, parent \rightarrow product) of the authentic amino acids were as follows: *N*-Me-L-Phe (25.3, 180 \rightarrow 134), *N*-Me-D-Phe (47.3). Compound-dependent MS parameters were as follows: DP 30, EP 10, CEP 13, CE 20, CXP 3. Source-dependent MS parameters were as follows: CUR 50, CAD medium, IS 5500, TEM 750, GS1 70, GS2 70.

Advanced Marfey's Analysis. The *N*-benzoyl *O*-methyl esters of (2*R*,3*R*)- and (2*R*,3*S*)-2-methyl-3-aminobutyric acid (Maba) were treated with 6 N HCl at 110 $^{\circ}$ C for 22 h. The products of each reaction were dried down and made up to 50 mM solutions in water. Then, 10 μ L of 1 M NaHCO₃ and 50 μ L of 1-fluoro-2,4-dinitrophenyl-5-L-leucinamide (L-FDLA, 1% w/v in acetone) were added to 25 μ L of the Maba stock solutions. The mixtures were heated to 35 $^{\circ}$ C for 1 h with frequent mixing, then neutralized with 5 μ L of 2 N HCl, concentrated to dryness, and then reconstituted with 250 μ L of MeCN–H₂O (1:1). The FDLA derivative of the ozonolysis product of **3** was prepared in a similar way using \sim 45 μ g of starting material. Derivatives were analyzed by reversed phase HPLC [column, Kinetex 2.6 μ m C18 100A (4.6 mm \times 100 mm), Phenomenex; flow rate, 0.5 mL/min; ESIMS detection in negative ion mode], using a MeOH–H₂O (both with 0.1% HCOOH) linear gradient (40–100% MeOH over 50 min). Under these conditions two peaks were detected in the L-FDLA derivative of the ozonolysate of **3**, corresponding to (2*R*,3*R*)- and (2*S*,3*R*)-Maba-L-FDLA, respectively, in the ratio 1.51:1. This is consistent with the extent of epimerization at the 2-position observed after treatment of the standards with acid,¹² allowing the assignment of (2*R*,3*R*)-Maba. The retention times (t_R , min) of the authentic standards were as follows: (2*R*,3*S*)-Maba-L-FDLA (25.6), (2*R*,3*R*)-Maba-D-FDLA⁴³ (25.6), (2*R*,3*R*)-Maba-L-FDLA (27.1), (2*R*,3*S*)-Maba-D-FDLA⁴⁴ (27.5).

Attempted Interconversion of Grassyseptolides A (1) and C (3). Compounds **1** and **3** were dissolved in CDCl₃ (150 μ L) and transferred to a 2.5 mm NMR tube. Pyridine-*d*₅ (0.5 μ L) was added, and the tube was heated at 60 $^{\circ}$ C for 72 h. Conversion was assessed by ¹H NMR.

Molecular Modeling of Grassyseptolide C (3). Because of the general similarity of proton and carbon chemical shifts of **1** and **3**, the same distance and angle constraints were used as in the previously reported modeling of **1**,¹² except that the amide bond between *N*-Me-Phe and Pro was set to *cis* due to a ROESY correlation between H-28 and H-38 in **3**. Also, four additional distance constraints were added on the basis of ROESY correlations unique to **3**. The modeling procedure used was identical to that previously used for **1**,¹² with 10 random structures of **3** being subjected to (1) minimization, (2) distance geometry, (3) minimization, and (4) molecular dynamics in Sybyl 7.3. Constraints were applied at every step, and the distance geometry procedure consisted of bounds generation, bounds smoothening, and embedding of coordinates, followed by an optimization procedure where the structures were minimized and subjected to simulated annealing (SA, 2000 to 200 K over 100,000 fs, step time 0.3 fs) and then another round of minimization. Dynamics were run at 500 K for 1 ns, with a step size of 1 fs. Following simulation, structures were overlaid in PyMol by pair-fitting backbone carbons only.

Cell Viability Assays. HT29 and HeLa cells were cultured in Dulbecco's modified Eagle medium (DMEM; Invitrogen) containing 10% fetal bovine serum (Hyclone) in a humidified atmosphere containing 5% CO₂ at 37 $^{\circ}$ C. Cells were seeded into 96-well plates at a density of 10 000 cells/well (HT29) or 3 000 cells/well (HeLa) in 100 μ L of medium. After 24 h, compounds **1**–**3** were added to wells at varying concentrations (as 1 μ L stock solutions in DMSO). Taxol was used as a positive control for cytotoxicity, and DMSO alone was used as a negative control. After 48 h of treatment the plates were developed with MTT dye according to the manufacturer's protocol (Promega). Taxol exhibited IC₅₀s of 2.2 and 1.7 nM for HT29 and HeLa cells, respectively.

Cell Cycle Analysis. HT29 cells were seeded in 6 cm dishes (650 000 cells/dish in 3 mL of DMEM). After 24 h of incubation,

(42) Jayaraman, M.; Srirajan, V.; Deshmukh, A. R. A. S.; Bhawal, B. M. *Tetrahedron* **1996**, *52*, 3741–3756.

(43) Corresponding in t_R to its enantiomer (2*S*,3*S*)-Maba-L-FDLA.

(44) Corresponding in t_R to its enantiomer (2*S*,3*R*)-Maba-L-FDLA.

various concentrations of **1** and **3** were added to the dishes, in 10 μL of DMSO. After a further 24 h, cells were washed with PBS and then detached with 600 μL of trypsin (Invitrogen). DMEM (2 mL) was added to each dish, and the cell suspensions were centrifuged at 650g for 10 min. The supernatant was discarded, and the cells were resuspended in 500 μL of PBS and centrifuged again at 650g for 10 min. The supernatant was discarded, and the cells were resuspended in 300 μL of PBS before 700 μL of ice-cold EtOH was added. Cells were incubated at $-20\text{ }^\circ\text{C}$ for 30 min, and then centrifuged at 890g for 10 min. The EtOH/PBS was removed, and then cells were resuspended in 500 μL of PBS containing 1 mM EDTA and 1 mg/mL RNase A (Sigma). The cells were incubated at $37\text{ }^\circ\text{C}$ for 30 min, with shaking, and then 5 μL of propidium iodide (1 mg/mL, Invitrogen) was added to each tube. Fluorescence from propidium iodide–DNA complexes was quantified using FACScan (Becton Dickinson).

CD Spectra. Aliquots of **1** (200 μg) were added to various amounts of CuCl_2 in CH_2Cl_2 –MeOH (1:100, total volume 400 μL). Data were collected at $25\text{ }^\circ\text{C}$ in the range 200–350 nm.

Detection of Metal Complexes by MS. Solutions of **1** (10 μg /mL) were made containing various amounts of Cu^{2+} or Zn^{2+} in CH_2Cl_2 –MeOH (1:100) and directly infused the ESIMS at a rate of 10 $\mu\text{L}/\text{min}$. MS parameters were as follows: DP 113.5, EP 4.5, CEP 45, CUR 10, IS 5500, TEM 400, GS1 20, GS2 10.

Acknowledgment. This research was supported by the National Institutes of Health, NIGMS Grant P41GM806210. The 600 MHz 1 mm triple-resonance HTS cryogenic probe used for NMR of compounds **2** and **3** in CDCl_3 was developed through collaboration between U.F., the National High Magnetic Field Laboratory, and Bruker Biospin.⁴¹ K.A.A. wishes to acknowledge the National Science Foundation and the University of Florida for funding of the purchase of the X-ray equipment. This is contribution number 833 from the Smithsonian Marine Station. We thank Eusebio Juaristi for kindly providing standards for the Maba unit.

Supporting Information Available: CIF structure file for compound **2**, Tables S1–S3, energies and constraint violations of compound **3** models (Table S4), Figure S1, atomic coordinates of compound **3** models (Tables S5–S14), and NMR spectra for compounds **2** and **3**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Note Added in Proof: While this manuscript was under review, the first total synthesis of grassypeptolide A (**1**) was published, see: [Liu, H.; Liu, Y.; Xing, X.; Xu, Z.; Ye, T. *Chem. Comm.* **2010**, 46, 7486–7488], confirming the structure and bioactivity.